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The efﬁcacy of psychotherapy, pharmacotherapy and
their combination on functioning and quality of life
in depression: a meta-analysis
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Background. There is growing recognition of the importance of both functioning and quality of life (QoL) outcomes in
the treatment of depressive disorders, but the meta-analytic evidence is scarce. The objective of this meta-analysis of ran-
domized controlled trials (RCTs) was to determine the absolute and relative effects of psychotherapy, pharmacotherapy
and their combination on functioning and QoL in patients with depression.
Method. One hundred and ﬁfty-three outcome trials involving 29 879 participants with depressive disorders were iden-
tiﬁed through database searches in Pubmed, PsycINFO and the Cochrane Central Register of Controlled Trials.
Results. Compared to control conditions, psychotherapy and pharmacotherapy yielded small to moderate effect sizes
for functioning and QoL, ranging from g = 0.31 to g = 0.43. When compared directly, initial analysis yielded no evidence
that one of them was superior. After adjusting for publication bias, psychotherapy was more efﬁcacious than pharma-
cotherapy (g = 0.21) for QoL. The combination of psychotherapy and medication performed signiﬁcantly better for both
outcomes compared to each treatment alone yielding small effect sizes (g = 0.32 to g = 0.39). Both interventions improved
depression symptom severity more than functioning and QoL.
Conclusion. Despite the small number of comparative trials for some of the analyses, this study reveals that combined
treatment is superior, but psychotherapy and pharmacotherapy alone are also efﬁcacious for improving functioning and
QoL. The overall relatively modest effects suggest that future tailoring of therapies could be warranted to better meet the
needs of individuals with functioning and QoL problems.
Received 9 December 2015; Revised 30 September 2016; Accepted 4 October 2016; First published online 26 October 2016
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Introduction
A considerable number of meta-analyses published in
the last decade have clearly shown that both psycho-
logical and pharmacological treatments are efﬁcacious
for reducing symptoms in depression (Cuijpers et al.
2011, 2013; Spielmans et al. 2011). Recent literature,
however, has suggested that functioning and quality
of life (QoL) improvement might be equally important
for people with depression as their symptom amelior-
ation (Zimmerman et al. 2006; IsHak et al. 2011a; Lam
et al. 2015). The Canadian Network for Mood and
Anxiety Treatments (CANMAT) highlighted the need
for evidence-based interventions that demonstrate im-
provement in functioning (Lam et al. 2015). From a
clinical perspective, patients have prioritized function-
al over symptomatic outcomes and determined the
return to a normal level of functioning at work,
home or school as a signiﬁcant factor for remission in
depression (Zimmerman et al. 2006). Furthermore, im-
provement in QoL has been considered the ultimate
outcome measure that indicates whether certain treat-
ments have succeeded (IsHak et al. 2011a).
Despite the importance given to functioning and
QoL, both dimensions remain under-researched in
interventional studies (Kamenov et al. 2015). The
terms have been used interchangeably in previous
studies, but there is agreement that these concepts
are not identical (Lam et al. 2015). Generally, function-
ing refers to one’s performance in daily or social activ-
ities and QoL as one’s satisfaction with these activities
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and perception of his/her health (IsHak et al. 2002,
2011a).
The conclusions drawn from the few published
meta-analyses on functioning are limited. A review
by De Silva et al. (2013) assessed the effect of psycho-
social interventions on social functioning in depression.
The article, however, reported only data from low- and
middle-income countries. A later meta-analysis by
Renner et al. (2014) also assessed the effect of psycho-
therapy on social functioning. The study, however,
examined only the absolute efﬁcacy of psychological
interventions and certain functional difﬁculties such as
problems in daily activities were not considered in the
assessment of functioning. On the other hand, many
meta-analyses have included QoL as a secondary meas-
ure of efﬁcacy of various interventions (von Wolff et al.
2012; Spielmans et al. 2013). However, research so far
has been mainly fragmentary, focusing only on speciﬁc
types of treatments, and there exists only one narrative
systematic review analyzing the impact of pharmaco-
therapy and psychotherapy on QoL in depression
(IsHak et al. 2011b).
To our knowledge, there is no meta-analysis that
comprehensively assesses the efﬁcacy of interventions
primarily aimed at depression treatment on functioning
and QoL in depression. Determining this efﬁcacy would
have important implications for clinical decisions and
policy making in terms of provision of treatments in pri-
mary and secondary mental health services. Therefore,
this meta-analysis of randomized controlled trials
aimed to assess (1) the effects of psychotherapy and
pharmacotherapy compared to control conditions on
functioning and QoL; (2) the effect of both when com-
pared directly, and (3) the effect of their combination
against either one. Additional sensitivity, subgroup
and meta-regression analyses were performed.
Method
Methods and results are presented according to the
PRISMA statement for reporting systematic reviews
(Moher et al. 2010).
Search strategy
A systematic literature search combining the terms de-
pressive disorder OR depression OR major depressive
disorder (Mesh terms) AND functioning OR disability
OR disability evaluation OR disabled persons OR sick
leave OR activities of daily living OR leisure activities
OR quality of life AND treatment OR intervention OR
clinical trial OR therapy (MeSH terms, key words and
text words) was performed in Pubmed, PsycINFO and
the Cochrane Central Register of Controlled Trials. In
the ﬁrst two databases, the relevant option was selected
to limit the search to Randomized Controlled Trials
(the full search string can be seen in Supplementary
material 3). Although non-randomized controlled trials
provide valuable information in terms of ecological
validity, RCTs minimize the inﬂuence of errors and
bias on ﬁndings and offer the most rigorous method of
determining whether a cause–effect relationship exists
between treatment and outcome (Sibbald & Roland,
1998; Spring, 2007). Their sole inclusion safeguarded
the validity of the ﬁndings and ensured methodological
consistency. The search was performed in June 2015. The
search was restricted by language (only articles pub-
lished in English were considered) and age (only partici-
pants aged >18 years). In addition, the references of
published meta-analyses and relevant articles were also
checked.
Study selection
The review included all randomized controlled trials that
compared (1) psychotherapy or pharmacotherapy
against treatment as usual (TAU), placebo, waiting
list (WL) or other control group: (2) psychotherapy
against pharmacotherapy; or (3) the combination of
psychotherapy and pharmacotherapy against either
one. Psychotherapy was deﬁned by the American
Psychiatric Association as ‘the informed and intentional
application of clinical methods and interpersonal stances
derived from established psychological principles for the
purpose of assisting people to modify their behaviors,
cognitions, emotions, and/or other personal characteris-
tics in directions that the participants deem desirable’
(Norcross, 1990). More speciﬁcally, different psycho-
therapeutic approacheswere deﬁned according to deﬁni-
tion previously developed in comparativemeta-analyses
(Cuijpers et al.2008a).All studies had to report at least one
validated outcome measure assessing functioning (any
difﬁculty experienced in maintaining daily activities or
participation in social life (Lam et al. 2015) or QoL
(one’s satisfaction with these activities and perception
of his/her health (World Health Organization Quality of
LifeGroup, 1997; IsHak et al. 2002). Informationon symp-
tom severity was extracted only from validated instru-
ments that explicitly measured symptoms of depression
[e.g. Hamilton Depression Rating Scale (HAMD;
Hamilton, 1960)]. The diagnosis of depression had to be
established by a standardized diagnostic interview
according to ICD or DSM criteria (APA, 1980, 1987,
2000; WHO, 1992). Studies including bipolar or schizo-
affective disorder or reporting results from maintenance
or continuation therapies were excluded. The abstract
screening was done by one researcher (K.K.) and a
random selection of 20% of the abstracts was double-
checked independently by another two researchers
(M.C. and C.T.).
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Data extraction and quality assessment
Data from the selected studies were extracted by one
researcher (K.K) and checked for consistency inde-
pendently by two other researchers. Divergences
were resolved by consensus. In case of missing data,
authors were contacted. When results from more
than one outcome measure assessing the same concept
(either functioning or QoL) were available in a study,
data from all were extracted and combined as a
mean effect size. To avoid double counting, the effects
of different intervention arms representing the same
generic intervention (e.g. GP-delivered psychotherapy
and clinician-delivered psychotherapy) included in a
single study were averaged and entered once in the
analysis (Senn, 2009). SF-36 (Ware & Sherbourne,
1992) was considered as an outcome measure of QoL
(IsHak et al. 2011b) but if a study reported post assess-
ment score on the social functioning subdomain, it
was included separately as an outcome measure of
functioning. Global measures of functioning were con-
sidered only if they included domains of social function-
ing and daily activities (De Silva et al. 2013). Data on
effect estimates were extracted at post-assessment. The
instruments were patient self-assessments and clinician-
rated tools.
Four criteria of the Cochrane Collaboration risk of
bias tool were used for assessing methodological
quality of the studies – sequence generation, allocation
concealment, blinding of assessors, and incomplete
outcome data (Higgins et al. 2011). It is impossible
for the majority of psychotherapeutic designs to em-
ploy a double blind design, therefore blinding of asses-
sors in these studies was adapted to include only
outcome assessors in masking procedures.
Statistical analyses
Statistical analyses were performed using the program
Comprehensive Meta-Analysis, version 2.0 (www.
meta-analysis.com/). The effect size for each individual
meta-analysis was calculated, aggregating the pooled
difference between the two groups of treatments at
the end of the intervention. Hedges’ g was preferred
as an effect estimate because of its capability to provide
a better effect estimate for small sample sizes (Deeks
et al. 2008). The magnitude of the effect size may be
interpreted as small (0.2), medium (0.5), and large
(0.8) (Cohen, 1988). We used a random effects
meta-analysis model which assumes that variance in
observed effects is explained not only by sampling
variability (as in ﬁxed effect analysis) but also real dif-
ferences in treatment effects resulting from heterogen-
eity in study populations, intervention delivery,
follow-up length and other factors (Riley et al. 2011).
To test the heterogeneity, Higgins’ I2 statistic was
calculated. A value of 0% indicates no heterogeneity,
25% indicate low heterogeneity, 50% – moderate het-
erogeneity, and 75% high heterogeneity (Higgins
et al. 2003). Publication bias was assessed in each of
the meta-analyses by visual inspection of the funnel
plots and the trim-and-ﬁll procedure to analyze the
changes after the accounting for publication bias
(Duval & Tweedie, 2000). In addition to the analyses
on functioning and QoL, we performed a series of indi-
vidual meta-analyses to assess the effect of psychother-
apy, pharmacotherapy and their combination on
depression symptom severity. The outcome was a re-
duction of symptom severity according to the instru-
ments’ scores.
In order to check the robustness of the results, sensi-
tivity analyses were conducted. First, the main ana-
lyses were repeated after exclusion of low-quality
studies. Then, to test whether one single outcome
measure had a strong impact on the overall effect
size, a series of sensitivity analyses were performed
after the exclusion of each of the instruments. Lastly,
the effect size was calculated for studies with a treat-
ment duration of43 months and compared with stud-
ies with a treatment duration of >3 months. The results
of the sensitivity analyses were considered ‘consistent’
with the primary analysis if there was no change in the
magnitude of the effect size (from high to moderate,
from moderate to small, etc.). Since the selected studies
were heterogeneous with respect to comparator
groups, study populations, included interventions
and outcome measures, series of subgroup analyses
were performed. We examined whether there were dif-
ferences in terms of age groups – adults (18–65 years)
v. older adults (>65 years), psychotherapies [Cognitive
Behavioral Therapy (CBT), Interpersonal Therapy
(IPT),ProblemSolvingTherapy (PST), others],medication
[selective serotonin reuptake inhibitors (SSRIs), sero-
tonin–norepinephrine reuptake inhibitors (SNRIs), tricyc-
lic antidepressants (TCAs), others], control groups (WL,
TAU, Placebo, others), outcome measures, duration of
treatment (3monthsv.>3months)andtypesofdepression
(major depressive disorder, dysthymia, subthreshold de-
pression, others).Long-term effects were not assessed, be-
cause a very small number of studies reported any
follow-updataand the reportedoutcomesdifferedwidely
between studies. Follow-up periods differed signiﬁcantly
(e.g. 3 months v. 12 months) and the nature of the follow-
upswas different: some studies reported only naturalistic
outcomes, whereas others delivered booster sessions and
maintenance treatments during the follow-up period. A
mixed-effects model, combining a random-effects model
within subgroups and a ﬁxed-effects model across sub-
groups, was used. Multivariate meta-regression analyses
were conducted using Stata v. 12.0 for Windows (Stata
Corporation, USA). In these analyses the outcome
416 K. Kamenov et al.
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variable was the weighted effect sizes of psychotherapy,
pharmacotherapy or their combination on functioning
and QoL at post treatment. The predictors were severity
of depression (effect size at post treatment), number of
psychotherapeutic sessions (where possible), duration of
treatment in weeks, duration of trial in weeks, and year
of publication. All the predictors used were continuous
variables. The regression coefﬁcient obtained from the
meta-regression analysis revealed how the intervention
effect changes with a unit increase in the predictors and
whether therewas a linear relationship between the inter-
vention effect and the predictors.
Results
Study selection
After removal of duplicates, 3447 articleswere identiﬁed
for abstract check. Of these, 354 were selected for full-
text screening. 153 articles met the inclusion criteria
and were included in the analyses. The main reasons
for exclusion were lack of functional or QoL measures
and non-standardized diagnosis of depression. Some
studies included outcome measures for both function-
ing and QoL, resulting in their inclusion in more than
one analysis. The selection process can be seen in Fig. 1.
Description of included studies
Selected characteristics of the studies can be seen in
Table 1. A total of 29 879 participants were included
in all trials. The majority of the participants were
adults aged between 18 and 65 years, and 60.1% of
all individuals had major depressive disorder. The dur-
ation of the trials ranged from 4 weeks to 1 year. The
most common psychotherapeutic intervention found in
the literature was CBT, based on two speciﬁc tasks –
cognitive restructuring and behavioral approach (such
as exposure and response prevention). Interpersonal ther-
apy – a structured therapy with a predominant focus on
addressing interpersonal issues – was also commonly
used in studies. The number and format of psychothera-
peutic sessions differed across studies, ranging between
4and20,weeklyandbi-weekly, individual andgroupses-
sions. We deﬁned pharmacotherapy as any treatment by
means of pharmaceutical drugs, e.g. antidepressants.
Fig. 1. Flow chart of study selection.
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The most frequently used drug in the studies was dulox-
etine. The dosage given to participants varied depending
on the type of drug and the duration of the trials.
In terms of instruments for measuring functioning,
the Sheehan Disability Scale (SDS; Sheehan, 1983)
and Social Adjustment Scale (SAS; Weissman et al.
1978) were the most commonly used ones, and for
QoL – the Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q; Endicott et al. 1993) and
SF-36. The majority of the trials were conducted in
USA, UK or The Netherlands. The quality of the stud-
ies varied. There were 47 trials (30.7%) meeting all four
quality criteria, whereas 75 studies (49%) were missing
two or more components. A full table including all
study characteristics and references of the included
articles can be found in Supplementary material 1.
Psychotherapy and pharmacotherapy v. control
condition
Fig. 2 provides information on the total effects of each
of the four individual meta-analyses (full details on
individual studies are available in Supplementary ma-
terial 2A and 2B). Compared to control conditions,
both psychotherapy and pharmacotherapy had small
to moderate effects on functioning, with slight superior-
ity of psychotherapy. The mean effect of psychotherapy
on functioning resulting from 52 comparisons was g =
0.43 [95% conﬁdence interval (CI) 0.33–0.54; I2 = 74.94,
95% CI 67.24–80.27]. After adjusting for publication
bias, the effect size decreased to 0.35 (95% CI 0.24–
0.46). For pharmacotherapy, the 53 comparisons yielded
an effect of g = 0.31 (95% CI 0.26–0.36; I2 = 64.91, 95% CI
51.66–73.21). After adjusting for publication bias, the ef-
fect size decreased to 0.27 (95% CI 0.21–0.32).
For QoL, both psychotherapy and pharmacotherapy
yielded small effect sizes. The 37 comparisons yielded
a mean effect of psychotherapy (g = 0.35, 95% CI 0.26–
0.44; I2 = 68.24, 95% CI 53.74–76.65). The effect of
pharmacotherapy coming from 33 studies was g =
0.31 (95% CI 0.24–0.38; I2 = 81.18, 95% CI 74.25–85.55).
Psychotherapy v. pharmacotherapy
For both functioning and QoL, there was no signiﬁcant
difference between therapies. In terms of functioning,
the mean effect size was 0.03 (95% CI −0.13 to 0.19;
I2 = 77.85, 95% CI 63.98–84.79) in favor of psychother-
apy (Fig. 3). After adjusting for publication bias,
Hedges’ gwas still insigniﬁcant, but increased substan-
tially to 0.12 (95% CI −0.06 to 0.30) in favor of psycho-
therapy. For QoL, the effect size was 0.05 (95% CI
−0.19 to 0.29; I2 = 90.72, 95% CI 84.47–93.71) in favor
of psychotherapy. After adjusting for publication
bias, the effect size was small, but signiﬁcant in favor
of psychotherapy (g = 0.21, 95% CI 0.01–0.43).
Combination of psychotherapy and pharmacotherapy
v. either one
The effects of the direct comparisons between combin-
ation of psychotherapy and pharmacotherapy against ei-
ther one on functioning or QoL are presented in Fig. 4.
In all four analyses, the combined treatment was signiﬁ-
cantly superior to each treatment alone yielding small ef-
fect sizes. For functioning, the 19 comparisons between
combined treatment andpharmacotherapyalone resulted
in effect size of g = 0.34 (95% CI 0.18–0.50; I2 = 69.51, 95%
CI 47.22–79.85) in favor of combined treatment. When
combined treatment was compared to psychotherapy
alone in 10 studies, the analysis yielded an effect size of
0.32 (95% CI 0.14–0.49; I2 = 66.98, 95% CI 21.02–81.43).
Six studies compared combined treatment against
pharmacotherapy and three against psychotherapy
on QoL. This weakened the power of the analysis.
Compared to medication, combined treatment was
signiﬁcantly more efﬁcacious (g = 0.36, 95% CI 0.11–
0.62; I2 = 66.91, 95% CI 0.00–84.11). The studies
Table 1. Selected characteristics of the included studies (N = 153)
Characteristic N (studies) %
Diagnosis
Major depressive disorder 92 60.1
Dysthymia 22 14.4
Subthreshold depression 10 6.5
Other 29 18.9
Target group
Adults 120 78.4
Older adults 15 9.8
Women 18 11.8
Type of psychotherapy
Cognitive Behavioral Therapy 31 31.3
Interpersonal Therapy 17 17.2
Problem Solving Therapy 9 9.1
Other 42 42.4
Type of pharmacotherapy
Selective serotonin reuptake
inhibitors
35 37.6
Selective serotonin and
norepinephrine reuptake inhibitors
31 33.3
Tricyclic antidepressants 19 20.4
Other 8 8.6
Study quality
42 75 49
53 78 51
Country
USA 71 46.4
UK 28 18.3
Netherlands 11 7.2
Others 45 29.4
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comparing combined treatment with psychological
interventions yielded an effect size of 0.39 (95% CI
0.19–0.58) in favor of combined treatment.
Effect of psychotherapy and pharmacotherapy on
depressive symptoms
Psychotherapy showed a better result (g = 0.60, 95% CI
0.51–0.68; I2 = 80.15, 95% CI 75.53–83.52) than
pharmacotherapy (g = 0.33, 95% CI 0.29–0.38; I2 =
54.37, 95% CI 35.77–65.71) when both interventions
were compared to control condition. After adjusting
for publication bias, the effect of psychotherapy
dropped to g = 0.45, whereas the effect of pharmaco-
therapy remained similar (g = 0.30). When both treat-
ments were compared directly, there was no
statistically signiﬁcant difference (g =−0.03, 95% CI
−0.15 to 0.10) in favor of medication. The combination
Fig. 2. Total standardized effect sizes (Hedges’ g) of psychotherapy and pharmacotherapy against control condition for
functioning and QoL.
Fig. 3. Standardized effect sizes (Hedges’ g) of psychotherapy against pharmacotherapy on functioning and QoL.
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Fig. 4. Standardized effect sizes (Hedges’ g) of combined treatment against psychotherapy and medication alone on
functioning and QoL.
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of treatments was superior to psychotherapy and
pharmacotherapy alone, yielding small effect sizes, g
= 0.30 (95% CI 0.16–0.45) and g = 0.34 (95% CI 0.18–
050), respectively.
Sensitivity and subgroup analyses
The sensitivity analyses revealed some major differ-
ences in the effects of psychotherapy, pharmacother-
apy and their combination on functioning and QoL
according to the duration of the interventions applied.
When psychotherapy was compared directly to medi-
cation on QoL, the trials with 43 months treatment
duration yielded an effect of g =−0.08 (95% CI −0.26
to 0.09) in favor of medication, whereas trials with a
treatment duration of >3 months showed superiority
of psychotherapy (g = 0.26, 95% CI −0.24 to 0.76). The
same applied for combined treatment against pharma-
cotherapy for QoL (g = 0.22, 95% CI −0.12 to 0.56 v. g =
0.64, 95% CI 0.37–0.92, respectively). The subsequent
subgroup analyses comparing the duration of treat-
ment, however, found no signiﬁcant differences
among studies. This might be due to low power be-
cause of the low number of studies included in the
analyses.
Furthermore, sensitivity analyses were performed
after the exclusion of low quality studies. For all ana-
lyses we found small deviations of the effect sizes,
which did not affect the magnitude of the effect esti-
mates. However, subgroup analyses were conducted
to compare high quality (meeting three or four com-
ponents of the Cochrane risk of bias tool) to low
quality (missing two or more components). Results
revealed signiﬁcant changes only in studies compar-
ing pharmacotherapy to control conditions on func-
tioning (high-quality studies: g = 0.26, 95% CI 0.21–
0.31 v. low quality: g = 0.36, 95% CI 0.28–0.44,
p = 0.05) and QoL (high quality: g = 0.22, 95% CI
0.11–0.33 v. low quality: g = 0.36, 95% CI 0.27–0.45
p < 0.05). Last, to investigate the impact of individual
outcome measures on the overall effect sizes, we con-
ducted a series of sensitivity analyses. Here, we
excluded one instrument at a time and examined con-
sequent deviations in effect sizes. For all analyses, we
found small deviations of the effect sizes of no more
than 0.10, which indicated that no individual outcome
measure had a strong impact on the overall effect
size. The subsequent subgroup analyses comparing
grouped studies according to the instruments used
did not show any signiﬁcant differences across
subgroups.
Differences in the effects of psychotherapy com-
pared to TAU, WL or placebo on functioning and
QoL were also assessed in subgroup analyses. The ef-
fect of psychotherapy on functioning was signiﬁcantly
higher (p < 0.05) in studies with waiting list controls
(g = 0.61, 95% CI 0.40–0.81) than in studies with TAU
(g = 0.36, 95% CI 0.24–0.48). The effect size of studies
comparing psychotherapy to waiting list (g = 0.47,
95% CI 0.34–0.59) on QoL was signiﬁcantly higher
(p < 0.05) than studies with TAU (g = 0.34, 95% CI
0.23–0.45) or placebo controls (g = 0.20, 95% CI 0.03–
0.37). Similar subgroup analyses could not be per-
formed for pharmacotherapy, as 95% of the studies
used placebo controls. Furthermore, clinician-rated
scales were compared to self-rated tools. Studies ap-
plying clinician-rated tools yielded slightly higher ef-
fect sizes in all analyses performed, but statistically
signiﬁcant differences were not found. Regarding age
groups, only studies comparing pharmacotherapy to
control condition for QoL revealed signiﬁcant differ-
ence between age groups (g = 0.35, 95% CI 0.27–0.42
for adults v. g = 0.16, 95% CI 0.04–0.27 for older adults).
The rest of the subgroup analyses did not reveal any
signiﬁcant differences across subgroups for depression
type (major depressive disorder, dysthymia, subthres-
hold depression, others), type of psychotherapy – CBT,
IPT, PST, or others, or type of medication – SSRIs,
SNRIs, TCAs, or others. All subgroups were directly
compared to each other, or each subgroup was com-
pared to the other subgroups pooled. All subgroup ana-
lyses are available upon request.
Meta-regression analyses
Multivariate meta-regression analyses assessing poten-
tial predictors were performed. The effect size of de-
pression severity was a signiﬁcant predictor of the
effects of psychotherapy and pharmacotherapy on
functioning (B = 0.59, 95% CI 0.42–0.76, p < 0.001 and
B = 0.94, 95% CI 0.59–1.29, p < 0.001, respectively) and
QoL (B = 0.35, 95% CI 0.1–0.61, p < 0.01 and B = 0.94,
95% CI 0.59–1.30, p < 0.001) when they were compared
to control conditions, and when pharmacotherapy was
compared directly to psychotherapy (B = 29.55, 95% CI
5.83–53.27, p < 0.05) and combined treatment (B = 0.001,
95% CI 0.0004–0.002, p < 0.01) for functioning. This
indicates when symptom severity is reduced, the
effect size of psychotherapy and pharmacotherapy on
improving functioning and QoL increases. The remain-
ing predictors – number of sessions, duration of treat-
ment, and duration of trial – were not signiﬁcant in any
of the meta-regression analyses we performed.
Number of sessions (B = 0.02, 95% CI 0.09–0.60, p <
0.05) and year of publication (B = 0.001, 95% CI
0.0003–0.002, p < 0.01) were found signiﬁcant only
when the effect of psychotherapy on QoL was com-
pared to control conditions. This indicated that the ef-
fect size of psychotherapy on QoL increases with
higher number of psychotherapeutic sessions and in
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recent publications. All analyses can be found in
Supplementary material 4.
Discussion
This meta-analysis was the ﬁrst to systematically assess
the effects of psychotherapy, pharmacotherapy and
their combination on improvements in functioning
and QoL in depressive disorders. The study demon-
strates that the combination between psychotherapy
and pharmacotherapy perform signiﬁcantly better
than each intervention alone for both outcomes.
Psychotherapy and pharmacotherapy alone are also
efﬁcacious for improving functioning and QoL, al-
though showing only small to moderate effects.
When compared directly, in initial analysis there was
no signiﬁcant difference between the interventions.
After adjusting for publication bias psychotherapy
was more efﬁcacious than pharmacotherapy for QoL.
Our results are consistent with the two previously
published meta-analyses on psychotherapy for social
functioning. Both Renner et al. (2014) and De Silva
et al. (2013) found effect sizes of g = 0.46 in favor of psy-
chotherapy over control condition, which was similar
to the result obtained in this study – 0.43. Even though
psychotherapy showed slightly superior absolute
effects to medication on both functioning and QoL, it
has to be noted that the great majority of included
pharmacological studies involved random assignment
to a blinded control condition as opposed to the psy-
chological trials, comparing interventions to WL or
TAU control groups. It has been argued that awareness
of treatment assignment might produce expectancy
effects in the intervention group and despair in the con-
trol group, leading to inﬂated effect sizes in favor of psy-
chotherapy. On the other hand, assignment to a blinded
condition controls for expectancy effects and induction
of hope, thus suggesting eventual underestimation of
the effects of medication compared to psychotherapy
(Gaudiano & Herbert, 2005). Nonetheless, a recent
meta-analysis by Cuijpers et al. (2015) comparing
pharmacological studies involving or missing double
blind condition to psychotherapy did not ﬁnd any differ-
ence in the effects of both groups.
We compared the effect of both interventions on func-
tioning and QoL but no signiﬁcant differences were
found. This is consistent with previous meta-analytic
evidence on depressive symptoms, where no superior-
ity was found for any of the intervention types
(Cuijpers et al. 2013). Still, when studies were adjusted
for publication bias, psychotherapy was slightly better
for improving functioning (g = 0.12) and statistically su-
perior than pharmacotherapy on QoL (g = 0.21). These
results, although suggesting the slight superiority of
psychological over antidepressant treatment for
functioning and QoL, are not robust enough to suggest
priority when clinical or policy decisions are made.
There is no clear economic evidence that psychotherapy
should be a preferable treatment choice compared to
pharmacotherapy (Bosmans et al. 2008). However, a re-
cent meta-analysis reveals a strong patient preference
for psychological treatment over medication (McHugh
et al. 2013). Moreover, evidence states that the majority
of people expressing personal preference for psycho-
logical therapy choose not to get treated at all rather
than receive medication (Layard et al. 2007). Alongside
the beneﬁts of pharmacotherapy for depression, it is
also worth taking into account that potential side-effects
and adverse events related to the use of medication may
have a detrimental impact on functioning and QoL. A
review by Kelly et al. (2008) showed that people with
depression experience diminished QoL related to
troublesome side effects. Further research is needed to
investigate the role of side effects in the efﬁcacy of inter-
ventions for depression. Even though the number of
studies directly comparing psychotherapy and pharma-
cotherapy was not very high, our results warrant future
research to determine the economic costs and beneﬁts of
eventual enhanced provision of psychotherapeutic
treatment.
The subgroup analyses found higher effect estimates
for psychotherapy against waiting list compared to
TAU and placebo for functioning and QoL. This
ﬁnding was somewhat expected and consistent with
previous meta-analyses for depression (Cuijpers et al.
2008b). Waiting list control conditions involve no ac-
tual treatment and thus positive outcomes for psycho-
therapy are relatively easy to attain. Comparison to
treatment as usual is more demanding, because it
involves usual care provided in healthcare settings
and the effect estimate shows the true additional
beneﬁt of psychotherapy on the outcome. Although
not to a signiﬁcant level, we found that studies apply-
ing clinician-rated scales yielded slightly higher effect
sizes than studies that relied on self-rated tools. The ab-
sence of signiﬁcance may be partly explained by an ab-
sence of power– only a small number of studies used
clinician-rated tools. Tentatively, this trend is in line
with the results of previous psychotherapy
meta-analyses indicating that clinician-rated instru-
ments are associated with higher effect-sizes of func-
tioning and depressive symptom severity (Cuijpers
et al. 2010; Renner et al. 2014). In the absence of a
gold standard measure for functioning (Lam et al.
2015; Madden et al. 2015), inclusion of both types of
outcome measures may be warranted to facilitate com-
prehensive assessments in future meta-analyses.
Psychotherapy and pharmacotherapy showed
higher effect sizes on reducing depressive symptoms
although there was a strong indication for publication
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bias. When the effects of psychotherapy and pharma-
cotherapy on depressive symptoms were compared
to control conditions, psychotherapy showed better
results (g = 0.60 v. g = 0.33, respectively). This result,
however, has to be considered with caution, because
in studies directly comparing both interventions, we
did not ﬁnd a signiﬁcant difference between the inter-
ventions (g =−0.03). Moreover, a previous
meta-analysis (Cuijpers et al. 2013) found no superior-
ity of one intervention over another. Future
meta-analyses of comparative outcome studies should
shed more light on potential differences in efﬁcacy be-
tween psychotherapeutic and pharmacological treat-
ments. Such investigations should also take into
account patient preferences and costs.
The results from the meta-regression analysis sug-
gest that functioning and QoL improve when symp-
tom severity improves, but which is the leading
factor is still unknown. Previous research suggests
that functional recovery appears later than the symp-
tomatic one and certain level of impairment continues
even after the symptomatology is ameliorated, and
that depressive symptoms and QoL do not share
high proportion of common variance (Coryell et al.
1993; Trompenaars et al. 2006). The residual functional
impairment has been found to evoke relapse and recur-
rences (Vittengl et al. 2009); therefore functioning and
QoL should be directly targeted in the response and re-
mission criteria for a more comprehensive assessment
of treatment efﬁcacy. There are already steps in this
direction. Individual Burden of Illness Index for de-
pression was created to measure treatment impact
and recovery in depression by incorporating symptom
severity, functioning, and QoL outcomes (Cohen et al.
2013). Zimmerman et al. (2014) validated the
Remission from Depression Questionnaire, including
different domains of functioning and QoL along with
symptomatology. However, all attempts for imple-
mentation of such criteria are still in their infancy
and future research is warranted.
The present meta-analysis demonstrates that the
combination of psychotherapy and pharmacotherapy
is signiﬁcantly better than any of the treatments
alone for both functioning and QoL. The number of
studies comparing treatments for QoL was limited,
but still our result has an important clinical implication
for primary and secondary mental health professionals
when choosing their treatment lines. Recent data
showing the trends in treatment of depression report
decrease in the use of combined treatment and psycho-
therapy and a substantial increase in the prescription
of antidepressants (Gemmill et al. 2008; Marcus &
Olfson, 2010). This might be driven by various factors
such as availability of resources in terms of money and
personnel. However, a recent analysis by Sado et al.
(2009) shows that combined therapy for depression
appears to be cost-effective from health-care system
and social perspective. More cost effectiveness and
comparative long-term data on combined treatment
is needed (McAllister-Williams, 2006).
This study has to be seen in light of certain limita-
tions. First, half of the included trials had low quality.
This questions the robustness of the results. However,
the sensitivity and subgroup analysis we performed
did not reveal signiﬁcant differences in the effects be-
tween high and low quality studies. Second, for some
of the individual analyses the number of studies was
not large enough to allow for generalizability of
results. Furthermore, mainly overall improvements in
functioning and QoL were assessed. There was a lack
of domain-speciﬁc reporting that could have provided
information on the effects of interventions on speciﬁc
areas of functioning and QoL. This meta-analysis was
based on study-level data. Individual patient level
meta-analysis based on original datasets of the
included studies could have revealed differences
among ﬁrst cases of depression and recurrent depres-
sion, level of severity, or allowed better analysis of pre-
dictors of depression. A further limitation was our
inability to analyze long-term outcomes and their inter-
actions, due to the lack of follow-up data. Follow-up
data would allow for investigating long-term effects of
interventions and temporal relationships between
changes in functioning, QoL and severity of symptoms.
Future longitudinal epidemiological studies could ﬁll
this research gap and provide important information
on the course of functioning in depression. Last, only
articles in English were considered. This might have
omitted relevant information.
In conclusion, this meta-analysis provides comprehen-
sive evidence that existing psychological and pharmaco-
logical interventions are efﬁcacious for improving
functioning and QoL in depression. There is no robust
evidence that one of the interventions is superior, al-
though psychotherapy appears slightly superior to
medication. The combination between psychotherapy
and medication performs signiﬁcantly better for both
outcomes when compared to each treatment alone.
The relatively modest effects suggest that future research
should focus on tailoring therapies to better cover the
needs of individuals, implementation of instruments
assessing both outcomes as primary outcome measures
in trials, and reporting domain-speciﬁc changes across
treatments for better understanding of the course of
depression.
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